TAF6L

Across TCGA pan-cancer cohorts, TAF6L RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of TAF6L’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where TAF6L RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TAF6L is over-expressed in tumor, although a few such as KICH and THCA show the opposite, repressed pattern.

BLCA, COAD, and HNSC are the cancer types where TAF6L tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TAF6L RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	All	+0.719	<.001	10	view →
COAD	Female	All	+0.696	<.001	10	view →
HNSC	Male	III,IV	+0.696	<.001	10	view →
KICH	Male	All	−1.010	<.001	9	view →
LIHC	Female	II,III,IV	+0.787	<.001	9	view →
THCA	Male	All	−0.359	<.001	9	view →
STAD	Male	II,III,IV	+0.907	<.001	8	view →
LUSC	All	II,III,IV	+0.757	<.001	8	view →
KIRP	Male	All	−0.488	.002	4	view →
UCEC	All	All	+0.324	.027	4	view →
KIRC	Male	All	−0.264	.001	4	view →
CHOL	All	All	+0.511	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

TAF6L–BLCA

Open the BLCA breakdown →